Autolus Therapeutics to Host R&D Day on March 26, 2019
March 07, 2019 16:05 ET
|
Autolus Therapeutics plc
Company to highlight next-generation, novel programmed T cell therapies in development for hematological and solid tumor indications Program and webcast to begin at 8:00 am ET LONDON, March 07,...
Autolus Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference
March 04, 2019 16:05 ET
|
Autolus Therapeutics plc
LONDON, March 04, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Present New Data on AUTO1 at the American Association of Cancer Research (AACR) Annual Meeting 2019
March 04, 2019 06:30 ET
|
Autolus Therapeutics plc
LONDON, March 04, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
June 26, 2018 09:15 ET
|
AUTOLUS LIMITED
Autolus Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares LONDON – 26 June 2018 – Autolus Therapeutics plc...
Autolus Announces Pricing of Initial Public Offering
June 21, 2018 21:52 ET
|
AUTOLUS LIMITED
Autolus Announces Pricing of Initial Public Offering LONDON – 22 June, 2018 – Autolus Therapeutics plc (“Autolus”), a clinical-stage biopharmaceutical company developing next-generation programmed T...
AUTOLUS LIMITED: Autolus Secures US$80 million Series C Funding
September 26, 2017 03:29 ET
|
AUTOLUS LIMITED
Autolus Secures US$80 million Series C Funding Proceeds will be used to establish clinical proof of concept for three novel haematological cancer programs London, 26 September 2017 -...